Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus PT from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned a consensus rating of “Hold” from the twenty analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $9.65.

SAGE has been the topic of several research analyst reports. Canaccord Genuity Group decreased their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday. HC Wainwright reissued a “neutral” rating and issued a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday. Truist Financial cut their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, October 30th. Stifel Nicolaus lowered their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday.

Sage Therapeutics Price Performance

NASDAQ:SAGE opened at $7.16 on Thursday. The firm’s fifty day moving average price is $6.34 and its 200 day moving average price is $6.93. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $27.39. The firm has a market cap of $437.98 million, a price-to-earnings ratio of -1.28 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. As a group, analysts expect that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP boosted its holdings in Sage Therapeutics by 2.0% in the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after acquiring an additional 111,123 shares during the period. State Street Corp boosted its holdings in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares during the period. Geode Capital Management LLC boosted its holdings in Sage Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock worth $6,827,000 after acquiring an additional 14,049 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock worth $2,510,000 after acquiring an additional 10,116 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Sage Therapeutics by 11.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company’s stock worth $1,343,000 after acquiring an additional 18,814 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.